Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GLYC |
---|---|---|
09:32 ET | 86860 | 0.2701 |
09:33 ET | 4159 | 0.2804 |
09:35 ET | 4057 | 0.2749 |
09:37 ET | 18706 | 0.2781 |
09:39 ET | 100 | 0.2812 |
09:42 ET | 354 | 0.2812 |
09:44 ET | 2045 | 0.2812 |
09:46 ET | 550 | 0.2812 |
09:48 ET | 300 | 0.2849 |
09:53 ET | 20000 | 0.2831 |
09:55 ET | 500 | 0.2839 |
10:00 ET | 200 | 0.2835 |
10:02 ET | 17526 | 0.280001 |
10:04 ET | 100 | 0.281 |
10:06 ET | 1475 | 0.2832 |
10:08 ET | 300 | 0.2855 |
10:09 ET | 14889 | 0.2901 |
10:11 ET | 4655 | 0.2895 |
10:15 ET | 500 | 0.2928 |
10:18 ET | 19051 | 0.2929 |
10:24 ET | 250 | 0.2928 |
10:27 ET | 11337 | 0.2931 |
10:29 ET | 965 | 0.2937 |
10:31 ET | 304 | 0.293599 |
10:36 ET | 180 | 0.290721 |
10:38 ET | 17503 | 0.29 |
10:40 ET | 10794 | 0.2934 |
10:42 ET | 400 | 0.2876 |
10:44 ET | 482 | 0.2876 |
10:45 ET | 650 | 0.2876 |
10:49 ET | 14490 | 0.288 |
10:51 ET | 8500 | 0.2928 |
10:58 ET | 1145 | 0.2898 |
11:02 ET | 477 | 0.2923 |
11:07 ET | 1973 | 0.2862 |
11:20 ET | 100 | 0.291 |
11:21 ET | 4600 | 0.292541 |
11:23 ET | 100 | 0.2936 |
11:27 ET | 10496 | 0.2933 |
11:32 ET | 100 | 0.2933 |
11:36 ET | 13774 | 0.291939 |
11:38 ET | 3280 | 0.2945 |
11:39 ET | 1300 | 0.29175 |
11:50 ET | 500 | 0.2948 |
11:54 ET | 100 | 0.2968 |
11:56 ET | 1450 | 0.2981 |
11:57 ET | 3635 | 0.29972 |
12:06 ET | 1000 | 0.2994 |
12:12 ET | 250 | 0.295 |
12:28 ET | 100 | 0.2959 |
12:30 ET | 2800 | 0.2947 |
12:33 ET | 300 | 0.2912 |
12:37 ET | 800 | 0.2933 |
12:42 ET | 2923 | 0.2934 |
12:50 ET | 366 | 0.291 |
12:53 ET | 1550 | 0.2913 |
12:55 ET | 2000 | 0.2935 |
01:02 ET | 1915 | 0.2906 |
01:04 ET | 100 | 0.2901 |
01:06 ET | 300 | 0.2957 |
01:09 ET | 304 | 0.291525 |
01:11 ET | 200 | 0.2916 |
01:13 ET | 700 | 0.2957 |
01:15 ET | 323 | 0.2957 |
01:20 ET | 5000 | 0.2901 |
01:24 ET | 1551 | 0.2956 |
01:26 ET | 900 | 0.2956 |
01:31 ET | 650 | 0.2955 |
01:45 ET | 100 | 0.2901 |
01:51 ET | 10000 | 0.2957 |
01:58 ET | 4717 | 0.2929 |
02:00 ET | 196 | 0.2957 |
02:03 ET | 5400 | 0.2957 |
02:07 ET | 196 | 0.2957 |
02:14 ET | 100 | 0.2921 |
02:20 ET | 167 | 0.2936 |
02:23 ET | 250 | 0.2977 |
02:39 ET | 3300 | 0.2903 |
02:50 ET | 100 | 0.294048 |
02:59 ET | 900 | 0.2941 |
03:01 ET | 192 | 0.2925 |
03:03 ET | 134544 | 0.2912 |
03:06 ET | 865 | 0.295199 |
03:21 ET | 3800 | 0.2865 |
03:24 ET | 200 | 0.2932 |
03:26 ET | 3100 | 0.2906 |
03:28 ET | 7401 | 0.2908 |
03:35 ET | 2600 | 0.2886 |
03:37 ET | 2500 | 0.29 |
03:42 ET | 6747 | 0.2941 |
03:44 ET | 4243 | 0.288901 |
03:46 ET | 400 | 0.293 |
03:48 ET | 200 | 0.293 |
03:50 ET | 600 | 0.293 |
03:51 ET | 4300 | 0.2935 |
03:55 ET | 500 | 0.29155 |
03:57 ET | 10288 | 0.2937 |
04:00 ET | 4065 | 0.2945 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
GlycoMimetics Inc | 19.0M | -0.5x | --- |
Kairos Pharma Ltd | 18.8M | -6.4x | --- |
Cocrystal Pharma Inc | 19.3M | -1.0x | --- |
Mira Pharmaceuticals Inc | 19.7M | -1.6x | --- |
Goldenwell Biotech Inc | 19.8M | -153.8x | --- |
MetaVia Inc | 19.9M | -0.5x | --- |
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.0M |
---|---|
Revenue (TTM) | $10.0K |
Shares Outstanding | 64.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.78 |
EPS | $-0.62 |
Book Value | $0.60 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 1,899.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -422,973.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.